Widgets for Webmasters
News source: Business Wire Emergent BioSolutions Inc. announced today that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases (NIAID) to fund the continued development of the company's rBOT and NGAV vaccine candidates. The rBOT grant is for the continued development, over a three-year period, of a serotype A and B recombinant botulinum vaccine. This is the first grant that Emergent BioSolutions has received for its botulinum vaccine program, and such support signals the U.S. government's confidence in the candidate. The NGAV grant provides important funding, over a five-year period, for animal model development and cGMP manufacturing of clinical lots of alternative formulations of a next generation anthrax vaccine, which may then be tested in a subsequent... [read full story]
